Pulsenmore Expands Its Home Ultrasound Activity in Israel: Ichilov Adopts the Technology, Expanding Access to At-Home Pregnancy Monitoring
Rhea-AI Summary
Pulsenmore (NASDAQ: PLSM) announced an expansion of its home ultrasound activities in Israel through integration of its technology at Lis Maternity and Women's Hospital at Ichilov, a major women's and maternity care center. Lis joins other Israeli medical centers that use Pulsenmore devices as part of pregnancy monitoring pathways.
The company now operates three models in Israel: a nationwide service with remote medical interpretation via Clalit Health Services; a Hospital at Home model used in several hospitals; and a hybrid model for high-risk pregnancies that combines in-hospital monitoring with at-home ultrasound scans under medical guidance.
Positive
- None.
Negative
- None.
Market Reaction – PLSM
Following this news, PLSM has gained 5.23%, reflecting a notable positive market reaction. Our momentum scanner has triggered 6 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $3.02. Trading volume is exceptionally heavy at 14.2x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 17 | AI grant | Positive | -4.1% | Israel Innovation Authority approved $1.27 million for SmartScan AI research and development. |
| Jul 13 | AI program | Positive | -6.2% | Pulsenmore was selected to lead a $1 million healthcare AI development project. |
| Jun 25 | Private placement | Negative | -10.5% | Pulsenmore priced a $7.5 million private placement with a healthcare-focused institutional investor. |
| Jun 24 | Strategic partnership | Positive | +93.3% | Pulsenmore partnered with Ouma Health to expand remote prenatal care across the United States. |
| Mar 30 | FY2025 results | Positive | +0.0% | Full-year revenue rose 374% and net loss improved to $5.0 million. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive announcements showed mixed reactions, including two negative AI-grant responses and one sharply positive partnership response.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Company's home ultrasound technology will be integrated at Lis Maternity and Women's Hospital at Ichilov, expanding the ability to incorporate at-home ultrasound scans as part of pregnancy monitoring
RAMAT GAN,
The addition of Lis expands Pulsenmore's presence in central
Pulsenmore's activities in
Dr. Elazar Sonnenschein, Founder and CEO of Pulsenmore:
"The addition of Lis marks another significant step in expanding access to home ultrasound in
About Pulsenmore
Pulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes prenatal care patient-centric, expanding access and improving continuity of care. For more information, visit www.pulsenmore.com
This press release contains forward-looking statements. In particular, statements using words such as "may," "seek," "will," "consider," "likely," "assume," "estimate," "expect," "anticipate," "intend," "believe," "contemplate," "do not believe," "aim," "goal," "due," "predict," "plan," "project," "continue," "potential," "positioned," "guidance," "objective," "outlook," "trends," "future," "could," "would," "should," "target," "on track" or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to the commercial potential of the integration at Lis Maternity and Women's Hospital at Ichilov. Forward-looking statements reflect Pulsenmore's current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company's lack of operating history; the Company's current and future capital requirements and the Company's belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company's ability to manufacture, market and sell its products and to generate revenues; the Company's ability to maintain its relationships with key partners and grow relationships with new partners; the Company's ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company's ability to launch and penetrate markets in new locations and new market segments; the Company's ability to retain key executive members and hire additional personnel; the Company's ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company's ability to achieve greater regulatory compliance needed in existing and new markets; the Company's ability to achieve key performance milestones in its planned operational testing; the Company's ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company's business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company's Annual Report on Form 20-F, filed with the SEC on March 30, 2026. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.
Investor Contact:
Miri Segal-Scharia
MS-IR LLC
msegal@ms-ir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/pulsenmore-expands-its-home-ultrasound-activity-in-israel-ichilov-adopts-the-technology-expanding-access-to-at-home-pregnancy-monitoring-302855031.html
SOURCE Pulsenmore Ltd.